Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis.
Stergios SoulaidopoulosDimitrios Terentes-PrintziosNikolaos IoakeimidisKonstantinos P TsioufisCharalambos VlachopoulosPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
The use of PDE5i primarily in men with or without known coronary artery disease was associated with a lower risk for cardiovascular events and overall mortality. This information underlines that PDE5i could provide clinical benefit beyond ED treatment and could instigate the conduction of further, large-scale randomized clinical trials.
Keyphrases
- cardiovascular events
- coronary artery disease
- cardiovascular disease
- emergency department
- percutaneous coronary intervention
- coronary artery bypass grafting
- middle aged
- type diabetes
- health information
- healthcare
- risk factors
- aortic valve
- combination therapy
- atrial fibrillation
- transcatheter aortic valve replacement
- aortic stenosis
- left ventricular
- replacement therapy